Prescribing Advice for GPs

An NHS Prescribing Advisers' Blog

SMC reject Exubera

The Scottish Medicines Consortium (SMC) has rejected Inhaled Insulin (Exubera®) for use on the NHS in Scotland.

The manufacturers failed to supply the economic analysis required to gain approval. The product was therefore rejected for use in both Type I and Type II diabetes.

The advice document contains a cost comparison table showing the comparative costs of current treatment options and inhaled insulin. The price range for inhaled insulin appears to be at least double that of existing treatments and depending upon dose equivalences this may be up to 8 times the price.

Action: Previous advice has recommended that inhaled insulin should not be initiated in primary care. The SMC advice suggests that this product should not be used at all.

Thanks to PharmaGossip, I had missed the original press release on this item.

Share 'SMC reject Exubera' on Email Share 'SMC reject Exubera' on Delicious Share 'SMC reject Exubera' on Digg Share 'SMC reject Exubera' on Facebook Share 'SMC reject Exubera' on Google+ Share 'SMC reject Exubera' on reddit Share 'SMC reject Exubera' on StumbleUpon Share 'SMC reject Exubera' on Twitter

atomic-wealth

No Comments to “SMC reject Exubera”

Leave a Comment

(required)

(required)


Prescribing Advice for GPs is powered by WordPress.
Subscribe for Free to our RSS or Atom Feeds for New Entries.
Akismet has protected Prescribing Advice for GPs from 789,668 spam comments.

atomic-wealth
fond-illness
summer